about
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibilityDiscovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyRandomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 TAccuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer.A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapyAssociation of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialValidation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBMTumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010.Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variantsAndrogen modulation of coregulator expression in prostate cancer cells.CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaRandomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction.Folate receptor-α (FOLR1) expression and function in triple negative tumorsIncreased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.The incidence of stroke after myocardial infarction: a meta-analysis.Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301)The incidence of ischemic stroke in chronic heart failure: a meta-analysis.Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations.Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients.Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial.Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome.Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence.Modified aesthetic abdominoplasty approach in perforator free-flap breast reconstruction: Impact of drain free donor site on patient outcomes.Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19.Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.Enhanced recovery after surgery in microvascular breast reconstruction.Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenograftsPhase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.Ischemic stroke after heart failure: a community-based study.Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels.
P50
Q24630647-3DCA3399-C934-445F-8950-D75700F9C783Q28534277-F3B6BAA5-9830-4CC3-9D90-528BDF6C938BQ30355704-8C5DDA2F-DA9F-4593-8E83-40B0FAA0CA18Q30405995-7953DB70-C5F6-4A12-B959-FF12A55240F6Q33375063-7896DD5A-2273-48CC-83A0-8DC092F31B8BQ33558891-FC552A46-2089-4CC6-B387-0619B3AABF70Q33699901-6A49264E-5902-45C1-9C2B-4D3E90AB231CQ33898869-7A297BFC-65E2-43B0-906A-A4519A1820B8Q33962175-1222FE54-3A6B-4CB0-AA52-DAA9A34BFB67Q34158197-DBDBF4CE-F405-4893-8FE0-3ACF164BC596Q34175379-09828EF8-D94A-4088-BFAD-4C446255C8AAQ34268364-9DD0CE33-AECF-4E85-B097-A754FC199FA2Q34407270-67B58CFC-2A53-48ED-99A2-E70EFC719B3EQ34639555-67711286-8CF5-4ED1-A6FC-DD014528D928Q34700954-A1C0FA93-D838-4BF2-B501-96DAD8E3D1C2Q34928162-0536A1DC-381F-43B5-9719-EC732757F546Q35105505-61534D4E-395D-43D5-A504-3640FC02AC0CQ35216750-3FB49743-6BBB-47D3-BE17-F0BB43B47736Q35225064-EEB38236-8E8D-4D70-8143-AB83ACA334E3Q36031031-7886507A-9553-4FDE-94F4-4A698EA53D83Q36431878-CE5B2B64-BF79-413F-A2C8-8E4119A503A3Q36893945-B093A510-C21E-4BCE-BE49-42A3AD5657AFQ36901285-248AAB31-CEF9-4989-9BDB-3C57DD69C586Q37308195-B9E2096A-90BA-4C52-9ABE-D986EEC45732Q37319009-4E61E393-9145-4E12-A423-86CD058312A0Q37412251-AAB3C331-0C8F-4E6A-BFAE-76567C65D021Q37576583-A401AB85-EE9F-429F-83C2-D90CEB580507Q37693530-C27C9F47-54EE-4147-8F38-26B13703CB52Q38230787-F6C72A26-48E2-4E94-8D86-7980FB758DCFQ38314252-0021ECA7-33DF-445C-9CCD-BF7F78A773F8Q38406640-E4CDCAE9-DF90-4816-9F73-12DA298A91F7Q38675845-6EE5AAF2-68E5-4588-A26D-AAE0130352D0Q40506611-0120F812-49A2-4CC8-A9E1-C4009DABD5A5Q41713778-2C630970-68BD-4001-BFE1-003A69F9D722Q42579908-FA712B22-E4E1-48D9-85C5-5B22A531AF64Q42671762-8C9316DB-320A-44AA-9936-EC0A4F639FADQ43542232-197C2C36-0512-4F0D-B6E4-4590AB8F91D7Q43674408-2C5D19EE-548C-4823-9D82-12D737319AD0Q43837061-4A761789-347B-47B6-8857-BCE03FDBACA2Q44174024-675EF497-5843-439C-B943-9C1CA352C29C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karla V Ballman
@ast
Karla V Ballman
@en
Karla V Ballman
@es
Karla V Ballman
@nl
Karla V Ballman
@sl
type
label
Karla V Ballman
@ast
Karla V Ballman
@en
Karla V Ballman
@es
Karla V Ballman
@nl
Karla V Ballman
@sl
prefLabel
Karla V Ballman
@ast
Karla V Ballman
@en
Karla V Ballman
@es
Karla V Ballman
@nl
Karla V Ballman
@sl
P106
P21
P31
P496
0000-0002-4492-0357
P569
2000-01-01T00:00:00Z